<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00868660</url>
  </required_header>
  <id_info>
    <org_study_id>ZP08-216</org_study_id>
    <secondary_id>AA75468</secondary_id>
    <nct_id>NCT00868660</nct_id>
    <nct_alias>NCT01429922</nct_alias>
  </id_info>
  <brief_title>Healthy Normal Single Ascending Dose and Crohn's Patient Multiple Ascending Dose</brief_title>
  <official_title>A Phase I, Double Blind, Placebo-Controlled Study of ZP1848 Administered as Subcutaneous Bolus Injections in Healthy Subjects Followed by Multiple Doses in Patients With Crohn's Disease in Remission</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zealand Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zealand Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Healthy Normal Single Ascending Dose and Crohn's patient Multiple Ascending Dose
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase I, Double blind, Placebo-controlled, safety and tolerability study of ZP1848
      administered as Ascending single Dose, SUBCUTANEOUS bolus injections in healthy SUBJECTS
      followed by a Multiple Dose cohort of patients with stable Crohn's disease in remission
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety and tolerability</measure>
    <time_frame>January2009-January2010</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>Jan 2009 - Jan 2010</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Inflammatory Bowel Disease</condition>
  <arm_group>
    <arm_group_label>ZP1848</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy Subjects or Crohn's Disease patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Healthy subjects or Crohn's Disease patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZP1848</intervention_name>
    <description>sc. bolus</description>
    <arm_group_label>ZP1848</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult male and/or females, 18 to 50 years of age

          -  Body mass index (BMI)18-30. Chrons Inclusion

          -  Adult male and/or females, 18 to 60 years of age (inclusive).

          -  Body mass index (BMI) ≥ 18 and ≤ 30 (kg/m2).

          -  Crohn's Disease Activity Index (CDAI) score &lt; 150.

          -  In a stable state of Crohn's disease as per the Investigator's opinion.

          -  Free of steroid treatment (therapy targeted for the GI tract only) within the 3 months
             prior to Day 1.

        Exclusion Criteria:

          -  History or presence of dysplasia, cancer, chronic hepatitis, HIV, tuberculosis (TB),
             or histoplasmosis.

          -  Fistula within the 3 months prior to dosing. 3. Ostomy (having ostomy now or at any
             time in the past). 4. Any surgery for the treatment of inflammatory bowel disease
             (IBD) within the 3 months prior to Day 1. 5. Short Bowel Syndrome (SBS). 6. Any other
             condition, chronic disease, or prior therapy, which in the opinion of the
             Investigator/Investigator's designee would put the patient at undue risk or would make
             the patient unsuitable for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Thorkildsen</last_name>
    <role>Study Director</role>
    <affiliation>Zealand Pharma A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CRI Worldwide</name>
      <address>
        <city>Willingboro</city>
        <state>New Jersey</state>
        <zip>08046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2009</study_first_submitted>
  <study_first_submitted_qc>March 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2009</study_first_posted>
  <last_update_submitted>November 1, 2010</last_update_submitted>
  <last_update_submitted_qc>November 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Christian Thorkildsen, Project Director</name_title>
    <organization>Zealand Pharma A/S</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

